ROS1-rearranged non-small cell lung carcinoma
Jump to navigation
Jump to search
ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]
General
- ROS1-rearrangements are seen in approximately 1-2% of non-small cell carcinoma.[2]
- Respond to target therapy, e.g. crizotinib.[3]
Microscopic
Features:
- Histology not definitive; however, predictive features are:[4]
- Cribriform structure.
- Psammoma bodies
Note:
- Most common pattern varies by specimen type:[4]
- Biopsy specimens: solid pattern most common.
- Resection specimens: acinar pattern most common.
Images
Related images
NSmCC - low mag.
NSmCC - intermed. mag.
NSmCC - high mag.
NSmCC - very high mag.
NSmCC - ROS1 - low mag.
NSmCC - ROS1 - intermed. mag.
NSmCC - ROS1 -high mag.
NSmCC - ROS1 -very high mag.
NSmCC - TTF-1 - high mag.
NSmCC - napsin A - high mag.
See also
References
- ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
- ↑ "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
- ↑ "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
- ↑ 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.